Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Stifel Nicolaus cut shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a report ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

Shares of Editas, the gene-editing company were down 23% at $1.45 on Friday. Editas announced a strategic shift, ending its development of reni-cel and cutting its workforce by 65%. The company ...

Buoyed by recent scientific progress in its in vivo pipeline, the Massachusetts-based firm is shifting focus to developing in ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on EDIT stock, giving a Hold rating yesterday.Pick the best stocks ...

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

Barclays analyst Gena Wang maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of $3.00. The ...

Editas ended the third quarter with cash reserves of around $256 million, down from $318 million three months earlier. It said at the time that was enough to fund operations to the middle of 2026, but ...